Third biological treatment gives more choice for people with severe asthma

NICE has published draft guidance today to say that benralizumab is cost-effective for use on the NHS in England and Wales by some adults who have severe eosinophilic asthma and have struggled to control it with inhalers. This uncommon and relatively uninvestigated form of asthma is believed to affect around 100,000 people in the UK. Benralizumab, made by AstraZeneca and also known as Fasenra, is a biological therapy which targets and depletes the immune cells (eosinophils) in the blood which cause the condition. More choice It is the third biological treatment for severe eosinophilic asthma approved for NHS use by